_id
691054d6ccc777a4e85d5597
Ticker
CRMD
Name
CorMedix Inc
Exchange
NASDAQ
Address
300 Connell Drive, Berkeley Heights, NJ, United States, 07922
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.cormedix.com
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Last Close
11.74
Volume
988005
Current Price
11.49
Change
-2.1294718909710393
Last Updated
2025-11-29T11:51:24.566Z
Image
data:image/webp;base64,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
Ipo Date
2010-03-25T00:00:00.000Z
Market Cap
772920576
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.9946461538461538
Sentiment Sources
26
Rating
4.5
Target Price
19
Strong Buy
3
Buy
3
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
104275289
Cost Of Revenue
11194616
Gross Profit
93080673
Operating Expenses
41734707
Operating Income
51345966
Interest Expense
948242
Pretax Income
52576178
Net Income
108562980
Eps
1.2592268077110447
Dividends Per Share
-
Shares Outstanding
78789045
Income Tax Expense
-55986802
EBITDA
57314886
Operating Margin
49.240780334830816
Total Other Income Expense Net
1230212
Cash
48493076
Short Term Investments
7223735
Receivables
160065050
Inventories
28916616
Total Current Assets
259535273
Property Plant Equipment
7520927
Total Assets
750861478
Payables
20454367
Short Term Debt
1423599
Long Term Debt
144528552
Total Liabilities
376732072
Equity
374129406
Depreciation
3790466
Change In Working Capital
-25651343
Cash From Operations
30856502
Capital Expenditures
505774
Cash From Investing
-291320443
Cash From Financing
150530924
Net Change In Cash
-109932741
PE
4.4389
PB
2.6477439199205848
ROE
29.01749455106985
ROA
14.45845647710802
FCF
30350728
Fcf Percent
0.29106347525922466
Piotroski FScore
3
Health Score
83
Deep Value Investing Score
6
Defensive Investing Score
6
Dividend Investing Score
3
Economic Moat Investing Score
10
Garp Investing Score
9
Growth Investing Score
8.5
Momentum Investing Score
4
Net Net Investing Score
2.5
Quality Investing Score
9.5
Value Investing Score
8.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
104275289
Quarters > 0 > income Statement > cost Of Revenue
11194616
Quarters > 0 > income Statement > gross Profit
93080673
Quarters > 0 > income Statement > operating Expenses
41734707
Quarters > 0 > income Statement > operating Income
51345966
Quarters > 0 > income Statement > interest Expense
948242
Quarters > 0 > income Statement > pretax Income
52576178
Quarters > 0 > income Statement > net Income
108562980
Quarters > 0 > income Statement > eps
1.2592268077110447
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
86214000
Quarters > 0 > income Statement > income Tax Expense
-55986802
Quarters > 0 > income Statement > EBITDA
57314886
Quarters > 0 > income Statement > operating Margin
49.240780334830816
Quarters > 0 > income Statement > total Other Income Expense Net
1230212
Quarters > 0 > balance Sheet > cash
48493076
Quarters > 0 > balance Sheet > short Term Investments
7223735
Quarters > 0 > balance Sheet > receivables
160065050
Quarters > 0 > balance Sheet > inventories
28916616
Quarters > 0 > balance Sheet > total Current Assets
259535273
Quarters > 0 > balance Sheet > property Plant Equipment
7520927
Quarters > 0 > balance Sheet > total Assets
750861478
Quarters > 0 > balance Sheet > payables
20454367
Quarters > 0 > balance Sheet > short Term Debt
1423599
Quarters > 0 > balance Sheet > long Term Debt
144528552
Quarters > 0 > balance Sheet > total Liabilities
376732072
Quarters > 0 > balance Sheet > equity
374129406
Quarters > 0 > cash Flow > net Income
108562980
Quarters > 0 > cash Flow > depreciation
3790466
Quarters > 0 > cash Flow > change In Working Capital
-25651343
Quarters > 0 > cash Flow > cash From Operations
30856502
Quarters > 0 > cash Flow > capital Expenditures
505774
Quarters > 0 > cash Flow > cash From Investing
-291320443
Quarters > 0 > cash Flow > cash From Financing
150530924
Quarters > 0 > cash Flow > net Change In Cash
-109932741
Quarters > 0 > ratios > PE
1.2592268077110447
Quarters > 0 > ratios > PB
2.6477439199205848
Quarters > 0 > ratios > ROE
29.01749455106985
Quarters > 0 > ratios > ROA
14.45845647710802
Quarters > 0 > ratios > FCF
30350728
Quarters > 0 > ratios > Piotroski FScore
3
Quarters > 0 > ratios > fcf Percent
0.29106347525922466
Quarters > 0 > health Score
83
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
39736790
Quarters > 1 > income Statement > cost Of Revenue
1862448
Quarters > 1 > income Statement > gross Profit
37874342
Quarters > 1 > income Statement > operating Expenses
18330837
Quarters > 1 > income Statement > operating Income
19543505
Quarters > 1 > income Statement > interest Expense
6671
Quarters > 1 > income Statement > pretax Income
20349488
Quarters > 1 > income Statement > net Income
19827981
Quarters > 1 > income Statement > eps
0.2757002275238191
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
71918624
Quarters > 1 > income Statement > income Tax Expense
521507
Quarters > 1 > income Statement > EBITDA
20519100
Quarters > 1 > income Statement > operating Margin
49.18239495439868
Quarters > 1 > income Statement > total Other Income Expense Net
805983
Quarters > 1 > balance Sheet > cash
159308966
Quarters > 1 > balance Sheet > short Term Investments
31402850
Quarters > 1 > balance Sheet > receivables
42911634
Quarters > 1 > balance Sheet > inventories
9634438
Quarters > 1 > balance Sheet > total Current Assets
248056889
Quarters > 1 > balance Sheet > property Plant Equipment
2054804
Quarters > 1 > balance Sheet > total Assets
252599103
Quarters > 1 > balance Sheet > payables
5815366
Quarters > 1 > balance Sheet > short Term Debt
177172
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
31968916
Quarters > 1 > balance Sheet > equity
220630187
Quarters > 1 > cash Flow > net Income
19827981
Quarters > 1 > cash Flow > depreciation
162941
Quarters > 1 > cash Flow > change In Working Capital
7290831
Quarters > 1 > cash Flow > cash From Operations
29991814
Quarters > 1 > cash Flow > capital Expenditures
23945
Quarters > 1 > cash Flow > cash From Investing
-20211776
Quarters > 1 > cash Flow > cash From Financing
83242199
Quarters > 1 > cash Flow > net Change In Cash
93023065
Quarters > 1 > ratios > PE
0.2757002275238191
Quarters > 1 > ratios > PB
3.7453849856003614
Quarters > 1 > ratios > ROE
8.986975567400485
Quarters > 1 > ratios > ROA
7.849584881542512
Quarters > 1 > ratios > FCF
29967869
Quarters > 1 > ratios > Piotroski FScore
4
Quarters > 1 > ratios > fcf Percent
0.7541592816128329
Quarters > 1 > health Score
79
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
39081657
Quarters > 2 > income Statement > cost Of Revenue
1596715
Quarters > 2 > income Statement > gross Profit
37484942
Quarters > 2 > income Statement > operating Expenses
17359662
Quarters > 2 > income Statement > operating Income
20125280
Quarters > 2 > income Statement > interest Expense
10007
Quarters > 2 > income Statement > pretax Income
20643898
Quarters > 2 > income Statement > net Income
20643898
Quarters > 2 > income Statement > eps
0.29929355411807723
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
68975418
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
20815847
Quarters > 2 > income Statement > operating Margin
51.495462436508255
Quarters > 2 > income Statement > total Other Income Expense Net
518618
Quarters > 2 > balance Sheet > cash
66285901
Quarters > 2 > balance Sheet > short Term Investments
11216989
Quarters > 2 > balance Sheet > receivables
54611147
Quarters > 2 > balance Sheet > inventories
7487708
Quarters > 2 > balance Sheet > total Current Assets
144861576
Quarters > 2 > balance Sheet > property Plant Equipment
2181832
Quarters > 2 > balance Sheet > total Assets
149582766
Quarters > 2 > balance Sheet > payables
1933136
Quarters > 2 > balance Sheet > short Term Debt
172495
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
34694718
Quarters > 2 > balance Sheet > equity
114888048
Quarters > 2 > cash Flow > net Income
20643898
Quarters > 2 > cash Flow > depreciation
161942
Quarters > 2 > cash Flow > change In Working Capital
-4615756
Quarters > 2 > cash Flow > cash From Operations
19736503
Quarters > 2 > cash Flow > capital Expenditures
10177
Quarters > 2 > cash Flow > cash From Investing
-194820
Quarters > 2 > cash Flow > cash From Financing
6092935
Quarters > 2 > cash Flow > net Change In Cash
25634847
Quarters > 2 > ratios > PE
0.29929355411807723
Quarters > 2 > ratios > PB
6.898259363062728
Quarters > 2 > ratios > ROE
17.96870811139554
Quarters > 2 > ratios > ROA
13.800986939899213
Quarters > 2 > ratios > FCF
19726326
Quarters > 2 > ratios > Piotroski FScore
3
Quarters > 2 > ratios > fcf Percent
0.5047464082702532
Quarters > 2 > health Score
84
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
31209936
Quarters > 3 > income Statement > cost Of Revenue
1175559
Quarters > 3 > income Statement > gross Profit
30034377
Quarters > 3 > income Statement > operating Expenses
17098369
Quarters > 3 > income Statement > operating Income
12936008
Quarters > 3 > income Statement > interest Expense
10007
Quarters > 3 > income Statement > pretax Income
13464404
Quarters > 3 > income Statement > net Income
13464404
Quarters > 3 > income Statement > eps
0.2189031078788935
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
61508510
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
13608086
Quarters > 3 > income Statement > operating Margin
41.4483643926729
Quarters > 3 > income Statement > total Other Income Expense Net
528396
Quarters > 3 > balance Sheet > cash
40650770
Quarters > 3 > balance Sheet > short Term Investments
11036857
Quarters > 3 > balance Sheet > receivables
51653583
Quarters > 3 > balance Sheet > inventories
7599535
Quarters > 3 > balance Sheet > total Current Assets
114575436
Quarters > 3 > balance Sheet > property Plant Equipment
2320713
Quarters > 3 > balance Sheet > total Assets
118845673
Quarters > 3 > balance Sheet > payables
1720177
Quarters > 3 > balance Sheet > short Term Debt
167922
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
34188723
Quarters > 3 > balance Sheet > equity
84656950
Quarters > 3 > cash Flow > net Income
13464404
Quarters > 3 > cash Flow > depreciation
133675
Quarters > 3 > cash Flow > change In Working Capital
-20581688
Quarters > 3 > cash Flow > cash From Operations
-5614536
Quarters > 3 > cash Flow > capital Expenditures
9869
Quarters > 3 > cash Flow > cash From Investing
-304161
Quarters > 3 > cash Flow > cash From Financing
11284844
Quarters > 3 > cash Flow > net Change In Cash
5364916
Quarters > 3 > ratios > PE
0.2189031078788935
Quarters > 3 > ratios > PB
8.348195628356562
Quarters > 3 > ratios > ROE
15.904664649506037
Quarters > 3 > ratios > ROA
11.329317812016598
Quarters > 3 > ratios > FCF
-5624405
Quarters > 3 > ratios > Piotroski FScore
2
Quarters > 3 > ratios > fcf Percent
-0.18021200043473334
Quarters > 3 > health Score
63
Valuation > metrics > PE
4.4389
Valuation > metrics > PB
2.6477439199205848
Valuation > final Score
100
Valuation > verdict
27.8% Undervalued
Profitability > metrics > ROE
29.01749455106985
Profitability > metrics > ROA
41.82975930211998
Profitability > metrics > Net Margin
1.0411189558055312
Profitability > final Score
100
Profitability > verdict
Adequate
Risk > metrics > Debt Equity
1.0069565929816273
Risk > metrics > Interest Coverage
54.148588651420205
Risk > final Score
70
Risk > verdict
Low
Liquidity > metrics > Current Ratio
11.862861154460154
Liquidity > metrics > Quick Ratio
10.541137919311145
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
62.546150143996385
Prev Valuations > 1
40
Prev Valuations > 2
40
Prev Profitabilities > 0
72
Prev Profitabilities > 1
96
Prev Profitabilities > 2
92
Prev Risks > 0
100
Prev Risks > 1
100
Prev Risks > 2
100
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2025-12-14T00:21:55.793Z
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Stock Price
$ 0.00
0% decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/ACormedix Stock Soars Pre-Market After Earnings Beat, Higher Full-Year Guidance MSN
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$19
Analyst Picks
Strong Buy
3
Buy
3
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Earnings Ratio (P/E)
-
Very High
Low ≥ 50
High ≤ 10
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very High
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very High
Low ≤ 5%
High ≥ 15%
Debt to Equity
-
Very Low
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 48.77% of the total shares of CorMedix Inc
1.
BlackRock Inc(7.1828%)
since
2025/06/30
2.
Vanguard Group Inc(5.7967%)
since
2025/06/30
3.
Marshall Wace Asset Management Ltd(3.4575%)
since
2025/06/30
4.
Vanguard Total Stock Mkt Idx Inv(3.1375%)
since
2025/07/31
5.
Citadel Advisors Llc(2.2972%)
since
2025/06/30
6.
State Street Corp(2.1464%)
since
2025/06/30
7.
Geode Capital Management, LLC(2.1392%)
since
2025/06/30
8.
iShares Russell 2000 ETF(2.0903%)
since
2025/08/31
9.
Nuveen, LLC(1.9682%)
since
2025/06/30
10.
Morgan Stanley - Brokerage Accounts(1.0282%)
since
2025/06/30
11.
Ghisallo Capital Management LLC(1.0051%)
since
2025/06/30
12.
Alyeska Investment Group, L.P.(1.0051%)
since
2025/06/30
13.
Vanguard Institutional Extnd Mkt Idx Tr(0.9796%)
since
2025/07/31
14.
Anson Funds Management LP(0.9716%)
since
2025/06/30
15.
Trexquant Investment LP(0.9487%)
since
2025/06/30
16.
Fidelity Small Cap Index(0.8643%)
since
2025/06/30
17.
Nuveen Quant Small Cap Equity R6(0.778%)
since
2025/07/31
18.
iShares Russell 2000 Growth ETF(0.7655%)
since
2025/08/31
19.
Northern Trust Corp(0.7602%)
since
2025/06/30
20.
Palisades Investment Partners, LLC(0.7538%)
since
2025/06/30
21.
Oberweis Asset Management Inc(0.65%)
since
2025/06/30
22.
Oberweis Micro-Cap(0.65%)
since
2025/06/30
23.
Oberweis Micro-Cap Growth(0.65%)
since
2025/06/30
24.
Kennedy Capital Management Inc(0.6435%)
since
2025/06/30
25.
Cubist Systematic Strategies, LLC(0.5564%)
since
2025/06/30
26.
iShares Biotechnology ETF(0.5291%)
since
2025/08/31
27.
Kennedy Micro Cap(0.5071%)
since
2025/06/30
28.
Fidelity Extended Market Index(0.4924%)
since
2025/07/31
29.
Two Sigma Investments LLC(0.4248%)
since
2025/06/30
30.
October Effect Ltd(0.4138%)
since
2025/06/30
31.
Driehaus Capital Management LLC(0.4117%)
since
2025/06/30
32.
Vanguard Russell 2000 ETF(0.4099%)
since
2025/07/31
33.
Palisades Small Cap Core(0.372%)
since
2025/06/30
34.
CREF Stock R3(0.3457%)
since
2025/07/31
35.
Strategic Advisers U.S. Total Stock(0.3357%)
since
2025/07/31
36.
Swedbank Robur Healthcare A(0.335%)
since
2025/07/31
37.
State St Russell Sm Cap® Indx SL Cl I(0.2905%)
since
2025/08/31
38.
SPDR® S&P Pharmaceuticals ETF(0.2444%)
since
2025/08/31
39.
Schwab Small Cap Index(0.2207%)
since
2025/07/31
40.
Vanguard US Momentum Factor ETF(0.2134%)
since
2025/06/30
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
No earnings data available.
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.